| Identification | Back Directory | [Name]
CDK5 inhibitor 20-223
(CP 668863) | [CAS]
865317-30-2 | [Synonyms]
CDK5 inhibitor 20-223
CDK5 inhibitor 20-223
(CP 668863)
2-Naphthaleneacetamide, N-(5-cyclobutyl-1H-pyrazol-3-yl)- | [Molecular Formula]
C19H19N3O | [MDL Number]
MFCD32857141 | [MOL File]
865317-30-2.mol | [Molecular Weight]
305.37 |
| Hazard Information | Back Directory | [Uses]
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent[1]. | [in vivo]
CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice[1]. | Animal Model: | Athymic nude mice[1] | | Dosage: | 8 mg/kg | | Administration: | Injections were given subcutaneously daily for the first week and every other day for two more weeks for a total of 14 injections. | | Result: | Reduced tumor growth and tumor weight in vivo. |
| [IC 50]
CDK2: 6.0 nM (IC50); CDK5: 8.8 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Caroline M Robb, et al. Characterization of CDK(5) Inhibitor, 20-223 (Aka CP668863) for Colorectal Cancer Therapy. Oncotarget. 2017 Dec 28;9(4):5216-5232. DOI:10.18632/oncotarget.23749 |
|
|